Status:
ENROLLING_BY_INVITATION
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Noonan Syndrome
Eligibility:
All Genders
Brief Summary
This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of N...
Eligibility Criteria
Inclusion
- Patients with a clinical and/or genetic diagnosis of NS
- Patients who are treated with Norditropin® (already treated or initiating) and who are followed in a participating center
- The decision to initiate treatment with commercially available Norditropin® has been made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
Exclusion
- Patients/Parents/LAR opposed to the collection and processing of their children's medical data
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Key Trial Info
Start Date :
March 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 17 2028
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT05308927
Start Date
March 16 2022
End Date
March 17 2028
Last Update
September 25 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire D'Angers-2
Angers, France, 49033
2
Ap-Hp-Hopital de Bicetre-2
Le Kremlin-Bicêtre, France, 94275
3
Hopital Des Enfants-2
Toulouse, France, 31059